Amendments to the Claims

The following listing of claims will replace all prior versions and listings of claims in the application.

1. (Currently amended) A method for **the treatment of gastrointestinal disorders comprising the** oral administration **of an aqueous suspension** via a gastric tube ~~of a~~ **or syringe to a patient in need of such treatment, wherein the aqueous suspension comprises (a) an aqueous carrier and (b) a** solid composition comprising **a therapeutically effective amount of** an acid labile proton pump inhibitor compound in the form of a multiple of enteric coating layered pellets in ~~a medium in the treatment of gastrointestinal disorders, wherein the pellets are in~~ admixture with **at least** one ~~or more~~ pharmaceutically acceptable **thickener which forms a viscous medium when dispersed in the aqueous carrier** ~~thickeners and an aqueous carrier and the thickener is capable of forming a viscous medium when dispersed in the aqueous carrier and the formed aqueous suspension is administered through a gastric tube or syringe to a patient in need of such a treatment~~.

2. (Currently amended) The method according to claim 1, wherein the thickener is selected from the group **consisting** of starch, xanthan gum, carrageenan, guar gum, locust bean gum, tragacanth, gelatin, pectin**,** ~~and~~ modified cellulose derivatives **and combinations thereof** ~~alone or in any combination~~.

3. (Original) The method according to claim 1, wherein the thickener is selected from starch and xanthan gum.

4. (Currently amended) The method according to claim 1, wherein the **solid** composition **further** ~~in addition~~ comprises **one or more** pharmaceutically acceptable additives selected from **the group consisting of** flavouring **agents** ~~agent~~, colour **agents** ~~agent~~ and sweetening **agents** ~~agent~~.

5. (Currently amended) A method for **the treatment of gastrointestinal disorders comprising the** oral administration **of an aqueous suspension** via a gastric tube ~~of a~~ **or syringe to a patient in need of such treatment, wherein the aqueous suspension comprises (a) a therapeutically effective amount of** ~~composition comprising~~ an acid labile proton pump inhibitor compound in the form of a multiple of enteric coating layered pellets and **(b)** ~~in a medium in the treatment of gastrointestinal disorders, wherein the medium is~~ a pharmaceutically acceptable viscous aqueous medium**, and wherein** ~~in which~~ the pellets are dispersed **in the viscous aqueous medium** to form **the aqueous** ~~an aqueous~~ suspension ~~and the formed suspension is administered through a gastric tube or syringe to a patient in the need of such treatment~~.

6. (Currently amended) The method according to claim 5, wherein the viscous aqueous medium is selected from **the group consisting of** yoghurt, sour milk, **and** syrup ~~and aqueous liquids with a similar viscosity~~.

7. (Original) The method according to claim 5, wherein the viscous aqueous medium is a sugar syrup with a sugar content of at least 63% by weight.

8. (Currently amended) The method according to **claim 1 or 5** ~~any of claims 1 and 5~~, wherein the viscosity of the **aqueous suspension is in the range of from** ~~formulation after gelation should be~~ 0.005 **to** [–] 10 Pa s, as determined at a shear rate of 10 s^{-1} from a flow-curve recorded on a rheometer equipped with a plate-plate geometry.

9. (Currently amended) The method according to **claim 1 or 5** ~~any of claims 1 and 5~~, wherein the viscosity of the **aqueous suspension is in the range of from** ~~formulation after gelation should be~~ 0.05 **to** [–] 5 Pa s, as determined at a shear rate of 10 s^{-1} from a flow-curve recorded on a rheometer equipped with a plate-plate geometry.

10. (Currently amended) The method according to **claim 1 or 5** ~~any of claims 1 and 5~~, wherein the **gastric tube has a** ~~aqueous suspension is administered through tubes with the~~ size **in the range of from** CH 5 to CH 10 (CH= Cherrier).

11. (Currently amended) The method according to **claim 1 or 5** ~~any of claims 1 and 5~~, wherein the **gastric tube has a** ~~aqueous suspension is administered through tubes with the~~ size **in the range of from** CH10 to CH20 (CH= Cherrier).

12. (Currently amended) The method according to **claim 1 or 5** ~~any of claims 1 and 5~~, wherein the proton pump inhibitor compound is selected from the group **consisting** of ~~compounds known under the generic names~~ omeprazole, lansoprazole, pantoprazole, rabeprazole, tenatoprazole, ~~and~~ esomeprazole **and** ~~or~~ a pharmaceutically acceptable salt thereof.

13. (Currently amended) The method according to **claim 1 or 5** ~~any of claims 1 and 5~~, wherein the amount of **proton pump inhibitor compound that is** administered ~~active substance~~ is **in the range from** 1 **to** [–] 100 mg.

14. (Currently amended) The method according to claim 1, wherein the aqueous carrier is selected from the group **consisting** of water, fruit juice, syrup and dairy products.

15. (Currently amended) The method according to **claim 1** ~~any of claims 1–5,~~ wherein the amount of **aqueous carrier** ~~administered viscous medium~~ is **in the range from** ~~approximately~~ 1 **to** [–] 35 mL.

16. (Currently amended) **A solid** ~~Solid~~ composition comprising a proton pump inhibitor compound in the form of a multiple of enteric coating layered pellets, wherein the pellets are in admixture with one or more thickeners capable of forming a viscous **suspension** ~~medium~~ when dispersed in an aqueous carrier.

17. (Currently amended) **The** [A] composition according to claim 16, wherein the enteric coated pellets are spherical and have a **diameter** [size] of less than 1 mm.

18. (Currently amended) **The** [A] composition according to claim 16, wherein the enteric coated pellets are spherical and have a **diameter** [size] of less than 0.5 mm.

Claim 19 (Canceled)

Claim 20 (Canceled)